Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma

Inclusion criteria

• Age greater than or equal to 18 years old, male or female;
• Relapsed or refractory CNS-involved large b-cell lymphoma after at least first-line therapy, with an efficacy assessment of CR or PR after salvage therapy, and current stable efficacy status;
• Eastern Cooperative Oncology Group (ECOG) score of 0-2;
• Have a life expectancy of ≥ 12 weeks
• Use contraception
• Have adequate bone marrow and organ function:

• Neutrophil count (anc) ≥1.0 x 109/L;
• Hemoglobin ≥ 8.0 g/dl;
• Platelet count ≥ 50 x 109/L;
• Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
• Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 x ULN or ≤ 5 x ULN (in the presence of hepatic invasion);
• Creatinine clearance ≥40mL/min
• Lipase ≤ 1.5 x ULN

Exclusion criteria

• Severe active central nervous system symptoms
• Prior chimeric antigen receptor cellular immunotherapy targeting cd19
• Known human immunodeficiency virus (hiv) infection or positive immunoassay;
• Live vaccination within 30 days prior to study drug administration;
• Active autoimmune disease requiring systemic therapy in the last 12 months
• Allergy to the study drug or history of severe allergic reactions
• Potential risk of malignant cardiac arrhythmia
• History of stroke or intracranial hemorrhage within 3 months prior to the date of administration of study medication
• Other malignant tumors presently or within 3 years prior to enrollment
• Conditions that, in the judgment of the investigator, would interfere with full participation in the study; pose a significant risk to the subject; or interfere with the interpretation of the study data
• Pregnant or lactating patients;